Swiss researchers have found a way to prevent the multiple disease relapses after responses to follicular lymphoma therapy.
AIM-listed Tiziana Life Sciences has a new head: The clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases appointed Kunwar Shailubhai Chief Executive Officer and Chief Scientific Officer.
Genome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia.
European venture capitalist Seventure Partners and Johnson & Johnson have invested US$12m in Israel-based DayTwo. Based on HbA1c, lifestyle factors and genetic analysis of the individual microbiome, the companys app analyses the individual microbiome to predict blood sugar responses to thousands of different foods.
Venture Capitalist Biogeneration Ventures has exceeded the target size of its life sciences fund BGV III through investments from the European Investment Banks InnovFin Equity Facility and the Dutch Venture Initiative II.
Belgian biopharmaceutical company Ablynx named Markus L.E. Ewert Chief Business Officer (CBO). Effective from 20 June 2017, Dr Ewert will lead the Company’s business development and corporate strategy activities and become a member of the Executive Committee.
The European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has recommended two antivirals, one biosimilar and two cancer meds for approval at its June meeting.
Uncertainty regarding the amount of future funding and political support from the European Commission for the bioeconomy is set to hamper investments into the switch from oil-based industry production to renewable, bio-based manufacture in Europe. The schedule for the review of the bioeconomy strategy has been delayed until the end of 2017. More importantly, it is not yet certain if the strategy will be updated.
A publication in Science Translational Medicine shows that Roche has a rising star in the 15 million patient market of age-related macular degeneration (AMD). In a Phase II trial, US and German researchers showed efficacy in geographic atrophy, an advanced stage of AMD, which has currently no treatment.
Rare disease drug developer Swedish Orphan Biovitrum AB (Sobi) has named Guido Oelkers as the companys new President and CEO. Oelkers, who holds a PhD in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London, joins from BSN Medical GmbH, where he held the position of CEO.